Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial
Xueli Bai, Xiang Li, Yiwen Chen, Guoliang Qiao, Qi Zhang, Tao Ma, Shunliang Gao, Min Zhang, Yan Shen, Jian Wu, Shuang Yu, Risheng Que, Xiao‐Chen Zhang, Ke Sun, Wenbo Xiao, Tianan Jiang, Tingbo Liang
Topics & Concepts
FOLFIRINOXMedicineGemcitabineHazard ratioRegimenInternal medicineOncologyClinical endpointNeoadjuvant therapyConfidence intervalAdverse effectSurgeryAdjuvantRandomized controlled trialPhases of clinical researchPancreatic cancerChemotherapyPancreatectomyOverall survivalAdjuvant therapyIntention-to-treat analysisSurvival rateFilgrastimSurvival analysisAntimetaboliteOxaliplatinClinical trialProgression-free survivalPancreatic and Hepatic Oncology ResearchCancer Genomics and DiagnosticsNeuroendocrine Tumor Research Advances